Pathophysiology and treatment of neurodegenerative disorders
Featured publications
-
Ikzf1 as a novel regulator of microglial homeostasis in inflammation and neurodegeneration
Ballasch, I; García-García, E; Vila, C; Pérez-González, A; Sancho-Balsells, A;(...)Gasull, X; Alberch, J; Rodríguez, MJ; Canals, JM; Giralt, A.Reference:Brain Behavior And Immunity 2023.
-
GPC3-Unc5 receptor complex structure and role in cell migration
Akkermans, Onno; Delloye-Bourgeois, Celine; Peregrina, Claudia; Carrasquero-Ordaz, Maria; Kokolaki, Maria;(...)Owens, Raymond J; Robinson, Carol V; Castellani, Valerie; del Toro, Daniel; Seiradake, Elena.Reference:Cell 2022.
-
Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington's disease mice
Pupak, A; Singh, A; Sancho-Balsells, A; Alcalá-Vida, R; Espina, M;Giralt, A; Martí, E; Orom, UAV; Ginés, S; Brito, V.Reference:Cellular And Molecular Life Sciences 2022.
-
Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder
Rosser, AE; Busse, ME; Gray, WP; Badin, RA; Perrier, AL;(...)Mills, LJ; Drew, C; Goldman, SA; Canals, JM; Thompson, LM.Reference:Brain 2022.
-
Huntington’s disease brain-derived small RNAs recapitulate associated neuropathology in mice
Creus-Muncunill, J; Guisado-Corcoll, A; Venturi, V; Pantano, L; Escaramís, G;(...)Masana, M; Llorens, F; Diaz-Lucena, D; Pérez-Navarro, E; Martí, E.Reference:Acta Neuropathologica 2021.
-
Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington's disease
Alcalá-Vida, R; Garcia-Forn, M; Castany-Pladevall, C; Creus-Muncunill, J; Ito, Y;(...)Samarajiwa, S; Peiró, S; Di Croce, L; Narita, M; Pérez-Navarro, E.Reference:Embo Molecular Medicine 2021.
-
M2 cortex-dorsolateral striatum stimulation reverses motor symptoms and synaptic deficits in Huntington's disease
Fernandez-Garcia, Sara; Conde-Berriozabal, Sara; Garcia-Garcia, Esther; Gort-Paniello, Clara; Bernal-Casas, David;(...)Campa, Leticia; Artigas, Francesc; Jose Rodriguez, Manuel; Alberch, Jordi; Masana, Merce.Reference:Elife 2020.
-
Increased translation as a novel pathogenic mechanism in Huntington's disease
Creus-Muncunill J; Badillos-Rodríguez R; Garcia-Forn M; Masana M; Barriga G;(...)Alberch J; Malagelada C; Delgado-García J; Gruart A; Pérez-Navarro E.Reference:Brain 2019.
-
Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens
Brito V; Giralt A; Masana M; Royes A; Espina M;Sieiro E; Alberch J; Castañé A; Girault J; Ginés S.Reference:Biological Psychiatry 2019.
-
Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation.
Cariulo C; Azzollini L; Verani M; Martufi P; Boggio R;(...)Santimone I; Squitieri F; Lashuel HA; Petricca L; Caricasole A .Reference:Proceedings Of The National Academy Of Sciences Of The United States Of America 2017.